Discontinuation of Beta-Blocker Therapy after Myocardial Infarction.
What's New
Discontinuing beta-blocker therapy more than one year after myocardial infarction was noninferior to continuing therapy in stable patients without heart failure.
Detailed Summary
An open-label, randomized, noninferiority trial across 25 centers in South Korea enrolled 2,540 stable post-MI patients with LVEF ≥40% and no heart failure. At a median follow-up of 3.1 years, discontinuation of beta-blockers was noninferior to continuation for a composite of death, recurrent MI, or heart failure hospitalization (HR 0.80; 95% CI, 0.57-1.13; P=0.001 for noninferiority).
Study Population
2,540 stable post-myocardial infarction patients (mean age 63.2 years, 12.8% women) with LVEF ≥40% and no heart failure, in South Korea
This research is for informational purposes only — discuss with your doctor before making any changes to your care.
Rivvet may earn a referral fee if you book through this link.